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Control of Fasciola hepatica infection in livestock is based on annual treatment using ﬂukicides such as
triclabendazole, albendazole and closantel. However, triclabendazole resistant F. hepatica populations are
emerging worldwide and resistance is emerging to albendazole, whereas it has until now never been
described for closantel. In Sweden, a topical formulation containing a combination of closantel and
ivermectin (Closamectin Pour On) has been registered for use in cattle only since 2011. This study
evaluated the efﬁcacy of closantel against F. hepatica in naturally infected beef cattle using both cop-
roantigen and faecal egg count reduction tests.
Faecal egg counts (FEC) and coproantigen ELISA examinations were conducted in February 2014 in
three beef cattle herds (A, B, C) in south-western Sweden. On each farm, 10 F. hepatica coproantigen-
positive and F. hepatica egg-positive animals were allocated after 12e16 weeks of housing into groups
and treated topically with a minimum of 20 mg closantel per kg body weight. Faecal samples were
collected from selected animals on 0, 7 and 21 day post-treatment (PT).
Based on FEC, closantel efﬁcacy 21 days PT was 72% (95% CI: 65e77%) and 97% (95% CI: 95e98%) on
farms A and B, respectively. No FEC reduction at all was observed on farm C. In total, 4, 1 and 6 animals
remained coproantigen-positive at 21 days PT on farms A, B and C, respectively.
Closantel treatment failure was conﬁrmed on two of the farms. As the animals were housed 12
e16 weeks before treatment and thereafter during the entire study, failure due to the presence of ju-
venile ﬂukes was excluded. Although the cause of closantel failure currently remains unclear, develop-
ment of resistance or/and absorption failure of topical administration should be considered. To our
knowledge, this is the ﬁrst report of closantel treatment failure against F. hepatica in cattle.
© 2015 The Authors. Published by Elsevier Ltd on behalf of Australian Society for Parasitology. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Control of fasciolosis in cattle and sheep is primarily based on
anthelmintic treatment using ﬂukicides. Triclabendazole (TCBZ) is
considered the drug of choice against Fasciola hepatica due to its
high efﬁcacy against both juvenile and adult stages in grazing
livestock (Fairweather, 2011a). Other ﬂukicides, such as closantel
(CLS), albendazole (ABZ) and nitroxynil, are also available on the
market, often in countries where TCBZ is not registered. However,
increasing numbers of cases of TCBZ resistance have recently been
reported in Australia, Europe and South America (Olaechea et al.,cal Sciences and Veterinary
rsity of Agricultural Sciences,
ilský).
Ltd on behalf of Australian Society f2011; Gordon et al., 2012a; Ortiz et al., 2013; Brockwell et al.,
2014), indicating that ﬂukicide resistance is a signiﬁcant concern
worldwide. However, it has also been proven that lack of ﬂukicide
efﬁcacy does not necessarily mean resistance (Fairweather, 2011b).
Under-dosing, inadequate storage of the anthelmintic, metabolic
changes, improperly applied anthelmintic and co-infection with
rumen ﬂukes may also explain observed treatment failure
(Fairweather, 2011b; Skuce and Zadoks, 2013; Hanna et al., 2015).
Lack of standardised guidelines, including treatment thresholds, for
resistance in F. hepaticamakes identiﬁcation of ‘true resistance’ and
‘treatment failure’ controversial.
Closantel is an anthelmintic drug belonging to the salicylanilide
derivate group and was ﬁrst discovered in the 1970s (Janssen and
Sipido, 1977). It is effective against immature F. hepatica aged 6
weeks and older, but not against juvenile ﬂukes (Fairweather and
Boray, 1999). Closantel uncouples ions involved in oxidativeor Parasitology. This is an open access article under the CC BY-NC-ND license (http://
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tion is not fully understood (Skuce and Fairweather, 1990). To date,
there have been no reports of closantel resistance against liver
ﬂukes and only one report of resistance against Haemonchus con-
tortus (Rolfe et al., 1990). The drug shows high efﬁcacy (95e100%)
against liver ﬂukes when applied/administered as an oral formu-
lation or by injection (Borgsteede et al., 2005, 2008; Mooney et al.,
2009). Furthermore, closantel treatment has repeatedly been
shown to be effective in sheep and cattle herds infected with TCBZ-
resistant F. hepatica populations (Coles et al., 2000; Gordon et al.,
2012b; Hanna et al., 2015). Thus, it has become an essential
second-line drug against TCBZ-resistant liver ﬂukes.
Although guidelines for diagnosis of anthelmintic resistance in
F. hepatica are lacking, there is agreement in the literature that the
faecal egg reduction test (FECRT) combined with other methods
such coproantigen reduction (Gordon et al., 2012b; Novobilský
et al., 2012; Brockwell et al., 2013; Hanna et al., 2015), detection
of ﬂuke DNA by polymerase chain reaction (PCR) (Robles-Perez
et al., 2013) and/or in vitro egg hatch test (Alvarez et al., 2009;
Fairweather et al., 2012; Canevari et al., 2014) provide reliable in-
formation about ﬂukicide efﬁcacy in naturally infected animals.
Furthermore, post-treatment ﬂuke histology (Hanna et al., 2010)
can show direct morphological damage in ﬂukes, but is not appli-
cable in common veterinary practice.
In Sweden, control of liver ﬂukes in sheep and cattle has for
decades been based solely on ABZ (Novobilský et al., 2012, 2015).
However, a new combination of closantel and ivermectin (mar-
keted as Closamectin, Norbrook, UK) as a pour-on formulation was
launched on the Swedish market in 2011. Immediately after regis-
tration, Closamectin Pour On became the key anthelmintic for
Swedish beef cattle herds infected with F. hepatica. However, the
Swedish Animal Health Service recently expressed concerns about
the efﬁcacy of the product in several beef cattle herds. In this study,
we evaluated the efﬁcacy of closantel in topical formulation against
natural F. hepatica infection in three Swedish beef cattle herds.
2. Materials and methods
2.1. Animals and study design
Three beef cattle farms (Farm A, Farm B, Farm C) located in
V€astra G€otaland in south-west Sweden were selected for the study.
Beef herds on farm A (coordinates: 5720057.300N, 1226029.800E), B
(coordinates: 5815058.200N, 1136001.600E) and C (coordinates:
5813049.000N,1136013.700E) consisted of 220, 75 and 120 Charolaise
and crossbreed cattle, respectively. All three farms have had a long
documented history with F. hepatica conﬁrmed bymeat inspection.
On all three farms, Closamectin Pour On (ivermectin þ closantel)
had been routinely applied at housing during January or February
in the three previous years. As the in-herd prevalence at meat in-
spection varied from 50 to 80%, only F. hepatica-positive animals
were selected using pre-screening sampling. In pre-screening,
faecal samples were collected from a randomly selected subsam-
ple of 25% of cattle in each herd. Samples were examined both by
coproscopy and coproantigen ELISA, as described below. Ten posi-
tive individuals identiﬁed both by sedimentation and coproantigen
ELISA were selected for treatment on each farm.
The study was performed as part of the routine control pro-
gramme by licenced veterinarians from Swedish Animal Health,
Sweden, and no ethical permission was required according to An-
imalWelfare Act 2009/021. Dewormingwas performed on all farms
in the second half of February 2014. At that time, the cattle had
been housed for 12e16 weeks and had no access to outdoor
pasture. All animals were last treated for liver ﬂuke 12 months
before the study. Beef cows selected on a pre-screening basis weredewormed with Closamectin Pour On Solution for Cattle® (Nor-
brook, UK) at the recommended dose, which corresponds to 20 mg
closantel per kg body weight. The drug used on all three farms
originated from the same commercial batch and it was stored in a
cool, dry, dark place in accordance with the manufacturer's
recommendation. All animals except those on farm Awereweighed
prior to drug application. Thus, dosing was accurate except on farm
A, where animals were dosed according to corresponding highest
cow weight obtained at the last scaling. All treated animals were
kept inside during the entire study, including drug application. At
the time of drug application, the hair on the spinal area of the
animals was dry, with no dermal injuries or contaminants.
Efﬁcacy of closantel was evaluated by faecal egg count (FEC) and
coproantigen ELISA. Faecal samples were collected at day 0 (just
before application), day 7 and day 21 post-treatment (PT). The 7-
and 21-day intervals were chosen based on previous studies (Moll
et al., 2000; Daniel et al., 2012; Brockwell et al., 2013, 2014; Hanna
et al., 2015).
2.2. Diagnostic procedures
Faecal samples were collected at the speciﬁed intervals directly
from the rectum of individual animals. Care was taken to ensure
that a clean rectal glove was used for every animal. Samples were
identiﬁed with animal ID on ear tags and immediately sent by mail
to our laboratory in Uppsala. The samples were stored at 4 C
during delivery and storage and processed immediately after
arrival. The maximum interval between sampling on the farm and
sample processing in the laboratory was 48 h. FEC were carried out
after sedimentation according to Thienpont et al. (1979) with some
modiﬁcation. In brief, 10 g of faeces were homogenised in ~100 ml
tap water and ﬁltered through 300 and 150 mm metal sieves. The
ﬁltered suspension was left to settle for 5 min in a 100-ml beaker
and then the supernatant was removed using a vacuum pump. This
procedure was repeated several times. The entire sediment was
observed and eggs were counted under a microscope at 40
magniﬁcation.
Coproantigen in faeces was determined using the commercial
BIO-X ELISA (BIO K 201, BIO-X Diagnostics, Belgium) with slight
modiﬁcations to the manufacturer's protocol as described by
Brockwell et al. (2013). The cut-off was optimised in our laboratory
by prior coproantigen ELISA examination of truly F. hepatica-posi-
tive and F. hepatica-negative faecal samples. These comprised 40
positive samples originating from three different beef F. hepatica-
positive herds where the infection status was conﬁrmed by
serology (Novobilský et al., 2014) and meat inspection data, and 40
negative faeces samples taken from the liver of a ﬂuke-free herd at
the SLU university farm in L€ovsta, Uppsala, Sweden. Infection-free
status of this herd was also veriﬁed by serology and sedimentation.
2.3. Molecular conﬁrmation of F. hepatica eggs in faecal samples
To conﬁrm the presence of F. hepatica eggs and exclude the
presence of paramphistomes (Paramphistomum cervi, Calicophoron
daubneyi) in faeces, polymerase chain reaction (PCR) was carried
out on DNA isolated from eggs concentrated during the sedimen-
tation process. DNA was obtained from the eggs both by chemical
disintegration used for Echinococcus eggs (Mathis et al., 1996) and
mechanical disintegration using a plastic pestle (Oberhauserova
et al., 2010). DNA from chemically and mechanically disrupted
eggs was isolated using DNeasy Blood and Tissue Kit (Qiagen,
Germany) according to the manufacturer's instructions. Egg DNA
samples were ampliﬁed using Ampli Taq Gold kit according to
Bazsalovicsova et al. (2010) with two pairs of internal transcribed
spacer 2 (ITS-2) primers speciﬁc for F. hepatica (Kralova-
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Further, a mitochondrial fragment of cytochromeoxidase-1 speciﬁc
for C. daubneyi was ampliﬁed according to Martínez-Ibeas et al.
(2013). The ampliﬁcation products were separated on 1% agarose
gel stained with GelRed™ Nucleic Acid Gel Stain (Biotium, USA).
F. hepatica and P. cervi adult DNA and DNA extracted from Galba
truncatula experimentally infected with C. daubneyi obtained from
previous studies (Bazsalovicsova et al., 2010; Novobilský et al.,
2013; Titi et al., 2014) were used as positive controls.
2.4. Statistical analysis
Calculation of closantel efﬁcacy based on FEC was determined
by two different methods: 1) FEC reduction was expressed as the
difference in arithmetic means between pre-treatment and post-
treatment levels with 95% conﬁdence limit, as recommended by
the World Association for the Advancement of Veterinary Parasi-
tology (Coles et al., 1992); 2) the percentage FEC reduction was
determined using Bayesian hierarchical models in the platform
‘eggCounts’ (http://www.math.uzh.ch/as/index.php?id¼254)
(Torgerson et al., 2014). Coproantigen levels were expressed as per
cent of positivity according to the manufacturer's protocol and
reduction in coproantigen levels was determined by the same
approach as for FEC (Brockwell et al., 2014; Coles et al., 1992). The
cut-off value in optimised coproantigen ELISA was identiﬁed by
receiver operating characteristic (ROC) curve analysis, using Graph
Pad Prism 5.02 (GraphPad Software, USA). The differences in FEC
and coproantigen values between pre- and post-treatment were
assessed by nonparametric ManneWhitney test with signiﬁcance
P < 0.05. Non-parametric Spearman correlation analysis was
applied to evaluate the relationship between FEC and coproantigen
values in the corresponding day's collection. P < 0.05 was consid-
ered signiﬁcant.
3. Results and discussion
The cut-off value for coproantigen ELISA obtained by ROC
analysis of 40 positive and 40 negative control samples was 1.6%
positivity. On farm A, one animal was slaughtered during the study
due to unknown health problems. The changes in FEC and cop-
roantigen levels during the study are summarised in Table 1. A
highly signiﬁcant (P < 0.001) decrease in FEC was observed on farm
B both 7 and 21 days PT. The faecal egg count reduction (FECR)
obtained by both methods was higher than 95%. Still, two cows in
herd B contained residual eggs 21 days PT. On farm A, FEC
decreased after application and at 21 days PT differed signiﬁcantly
(P < 0.05) from that obtained before treatment. However, the FECR
achieved was approx. 52% and 72% at days 7 and 21 PT, respectively.
FEC on farm C showed an increasing trend and no reduction at all
was observed. Only 3 of 10 animals were egg-negative 21 days PT
on farm C. Although mean percentage coproantigen positivity was
signiﬁcantly lower on day 21 PT, one coproantigen-positive cow
was observed on farm B. Interestingly, two individuals were
coproantigen-negative before treatment, despite the fact that all
animals had coproantigen and egg presence conﬁrmed by pre-
screening on farm B. On farm C, coproantigen values decreased
slightly on day 7 but increased again on day 21 PT. In total, six
animals excreted coproantigen 21 days PT, with only 35% reduction
in coproantigen positivity on farm C. FEC and coproantigen values
were signiﬁcantly correlated at day 21 PT and were close to
signiﬁcantly correlated at day 7 PT on both farms A and C (Table 2).
In contrast, the relationship between FEC and coproantigen values
was reversed, with a signiﬁcant correlation before treatment on
farm B.
In two faecal samples from farm C, high variability in egg size
Table 2
Spearman correlation analysis P-values between faecal egg counts (FEC) and cop-
roantigen (cAg) values within each group. (*P < 0.05; **P < 0.01).
cAg day 0 cAg day 7 cAg day 21
Farm A
FEC day 0 0.744
FEC day 7 0.050
FEC day 21 0.021*
Farm B
FEC day 0 0.003**
FEC day 7 0.218
FEC day 21 0.313
Farm C
FEC day 0 0.427
FEC day 7 0.060
FEC day 21 0.005**
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F. hepatica and lack of P. cervi and C. daubneyi (Fig. 1). Only samples
with mechanical disintegration of eggs tested positive for
F. hepatica. Isolation of DNA using chemical disintegration for tae-
niid eggs failed. In addition, cross-reaction between P. cervi and
C. daubneyi DNA samples was observed for P. cervi ITS-2 primers.
Rumen ﬂukes are sensitive to different spectrum of anthelmintics
than liver ﬂukes. Thus, co-infection of F. hepaticawith rumen ﬂukes
might affect FECR for F. hepatica (Skuce and Zadoks, 2013). From the
results it apparent that rumen ﬂuke eggs were not present in herd C
and therefore could not compromise our FEC data.
Our data showed that closantel treatment against adult live
ﬂukes in naturally infected beef cattle failed in two out of three
herds investigated. To our knowledge, this is the ﬁrst report of
closantel failure against F. hepatica in the world. Although the cause
of the failure is unclear, it raises serious concerns for beef cattle
producers world-wide.
Besides development of anthelmintic resistance, several other,
often neglected, factors may be responsible for treatment failure.
Underdosing, faulty drenching equipment, inadequate parasite
control programmes, inappropriate dosing, product failure, age of
product, reduced metabolism as a result of liver damage and
inadequate and incorrect diagnostic tests are important con-
founding causes of ﬂukicide failure (Fairweather, 2011a). In this
study, three different herds were treated using closantel originating
from the same product batch, by the same veterinarian and theFig. 1. Agarose gel electrophoresis of PCR products obtained by ampliﬁcation of DNA
samples using primers speciﬁc for (A) Fasciola hepatica, ampliﬁed region 112 bp
(Kralova-Hromadova et al., 2008), (B) Paramphistomum cervi, ampliﬁed region 161 bp
(Bazsalovicsova et al., 2010) and (C) Calicophoron daubneyi, ampliﬁed region 885 bp
(Martínez-Ibeas et al., 2013). The eggs tested originated from farm C, where high
variability in egg size was observed. (1) DNA isolated from egg suspension by chemical
disintegration; (2) DNA isolated from egg suspension by mechanical disintegration; (3)
DNA from F. hepatica adult; (4) DNA from P. cervi adult; (5) DNA from Galba truncatula
experimentally infected with C. daubneyi.same drenching equipment and in agreement with WAAVP
guidelines (Coles et al., 1992). Except farm A, where animals were
dosed according to the highest animal weight from previous
scaling, all animals on farm B and C were dosed according to their
speciﬁc weight recorded immediately before drug application.
Thus, incorrect dosing cannot be completely excluded as the cause
of failure on farm A. However, the clear difference in efﬁcacy be-
tween farms B and C suggests that all alternative factors listed,
including incorrect dosing, product failure and faulty drenching,
are very unlikely. Themost probable explanation for failure on farm
C is resistance or unknown problems with dermal absorption of the
drug. Thus, the cause of anthelmintic failure remains speculative at
this stage. However, standardised tests for detection of ﬂukicide
resistance in live animals are still lacking.
In previous studies, closantel efﬁcacy has been tested using per
oral (PO), intramuscular (IM) and/or subcutaneous (SC) adminis-
tration in sheep and cattle. The efﬁcacy of closantel in these studies
varied from 95 to 100% (Guerrero, 1984; Coles et al., 2000; Moll
et al., 2000; Borgsteede et al., 2008; Gordon et al., 2012b; Hanna
et al., 2015). While PO closantel administration at a dose of
10 mg/kg body weight is available for sheep, subcutaneous injec-
tion at a dose of 5 mg/kg body weight is available for cattle. In the
present study, a pour-on formulation containing closantel and
ivermectin was used, with doses of 20 mg and 500 mg per kg body
weight, respectively. This could mean that closantel failure in the
study is associated with the topical administration of the drug.
Nevertheless, recent data showed that closantel administered
topically has 68%, 90% and 99% efﬁcacy against 6-, 8- and 12-week-
old ﬂukes, respectively (Geurden et al., 2012). In our study, drug
application was performed in the second half of February, when all
animals had been housed for 12e16 weeks before drug application.
Thus, only adult ﬂukes were present in these animals. This clearly
conﬁrms that closantel failure on the Swedish farms studied was
not due to lower efﬁcacy against immature ﬂukes, which has been
shown in cattle and sheep in previous studies (Fairweather and
Boray, 1999; Geurden et al., 2012).
Closantel binds strongly to albumin in the blood and does not
metabolise and thus the closantel concentration in blood remains
high in comparison to that of benzimidazoles (Michiels et al., 1987).
Thus, exposure of ﬂukes to closantel is prolonged due to long half-
life and this provides activity against developing immature ﬂukes,
even though the drug acts intrinsically on the mature liver ﬂuke
(Cromie et al., 2006). According to pharmacokinetic data, closantel
in topical administration (Closamectin Pour On, closantel dose
20mg/kg) (Cmax¼ 68.5 mg/ml; Tmax¼ 120 h, AUC¼ 35 207 mg h/ml)
achieves higher concentrations in plasma (Norbrook, 2015) than
when administered orally (Cmax ¼ 59.8 mg/ml; Tmax ¼ 67 h,
AUC ¼ 21 564 mg h/ml) or subcutaneously (Cmax ¼ 63.4 mg/ml;
Tmax ¼ 54 h, AUC ¼ 21 996 mg h/ml) (Cromie et al., 2006). This
further conﬁrms that administration route cannot be associated
with closantel failure in this study. On the other hand, PO appli-
cations of TCBZ are often superior to pour-on applications
(Hutchinson et al., 2009; Martin et al., 2009). For closantel, no
comparison between the efﬁcacy of per oral, subcutaneous and
topic formulations has yet been available.
A combination of FEC and coproantigen ELISA is generally
accepted as the optimal method for diagnosis of efﬁcacy/resistance
in F. hepatica (Flanagan et al., 2011; Gordon et al., 2012b; Brockwell
et al., 2013; Hanna et al., 2015). However, interpretation of data
from FEC and coproantigen ELISA and their combination and
particularly thresholds for both tests are unclear. According to
WAAVP guidelines 95% or 90% efﬁcacy has been applied as the
threshold for FECR (Coles et al., 1992). However, WAAVP guidelines
were originally designed for gastrointestinal nematode and not for
ﬂukes. In addition, disadvantages of FEC as regards irregular
A. Novobilský, J. H€oglund / International Journal for Parasitology: Drugs and Drug Resistance 5 (2015) 172e177176excretion of eggs from the gall bladder have been reported
(Flanagan et al., 2011). In our study, FECR was apparently <90% on
farms A and C, but >95% on farm B. Coproantigen results for these
three herds were more complex. Although percentage cop-
roantigen positivity decreased in all three groups 21 days PT in
comparison with pre-treatment values, the numbers of
coproantigen-positive animals on day 21 PT differed (Table 1). Even
on farm B, where FECR was >95% and coproantigen was reduced
signiﬁcantly (P < 0.001), two cows had a few eggs in faeces and one
coproantigen-positive animal was observed 21 days PT. Similarly,
Flanagan et al. (2011) detected one coproantigen-positive sheep in
a group successfully treated with TCBZ where no ﬂukes were found
after treatment and FECR was 95e98%. They attributed this ﬁnding
to a false-positive reaction due to slow release of disintegrated
fragments of ﬂukes from the liver.
Interestingly, FEC and coproantigen values within the test group
and the corresponding sample collectionwere positively correlated
after treatment on farms A and C, where closantel failure occurred,
but before treatment on farm B. The signiﬁcant correlation between
FEC and coproantigen further conﬁrmsmutual and complementary
application of both methods for ﬂukicide efﬁcacy/resistance
detection, as described previously (Flanagan et al., 2011;
Novobilský et al., 2012; Brockwell et al., 2013).
Limitations of FEC as regards irregular release of F. hepatica eggs
and the fact that commercial coproantigen ELISA can give both
false-negative (Gordon et al., 2012b; Novobilský et al., 2012;
Brockwell et al., 2013) and false-positive results (Flanagan et al.,
2011) make interpretation of ﬂukicide efﬁcacy very complicated,
especially under ﬁeld conditions. Thus, there is an urgent need for
standardised protocols for evaluation of ﬂukicide efﬁcacy, espe-
cially for thresholds applied for FEC and coproantigen ELISA.
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